Potential role of vascular targeted therapy to combat against tumor (Q33470615)

27 July 2017

1 reference

title

Potential role of vascular targeted therapy to combat against tumor (English)

1 reference

27 July 2017

Bei Chen

1

1 reference

27 July 2017

Haifeng Jin

series ordinal

2

1 reference

27 July 2017

Kaichun Wu

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Drug Delivery

27 July 2017

published in

1 reference

27 July 2017

volume

6

1 reference

27 July 2017

issue

7

1 reference

27 July 2017

page(s)

719-726

1 reference

Tumor angiogenesis: therapeutic implications

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Targeting the tumor vascular compartment to improve conventional cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Cellular abnormalities of blood vessels as targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Resistance in the anti-angiogenic era: nay-saying or a word of caution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Integrins: roles in cancer development and as treatment targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Vascular targeting: recent advances and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Combretastatin A4 phosphate: background and current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Thrombosis associated with angiogenesis inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Tumor vasculature-targeted delivery of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Review: side effects of approved molecular targeted therapies in solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Mapping tumor vascular diversity by screening phage display libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Molecular profiling of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Genes that distinguish physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Searching for Peptide Ligands with an Epitope Library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Targeting tumor vasculature with homing peptides from phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Adventures with an enigmatic anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Biopanning and rapid analysis of selective interactive ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Steps toward mapping the human vasculature by phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Tumour-homing peptides: tools for targeting, imaging and destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Peptides homing to tumor vasculature: imaging and therapeutics for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection--study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018871

10.1517/17425240903018871

21 January 2018

Identifiers

DOI

1 reference

27 July 2017

1 reference